Bei Akademie registrieren
VRCA, US92511P1021

VRCA stock needs a stronger catalyst on September 3, 2026

Published on 09/03/2026 at 19:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
VRCA stock has little fresh market support visible on September 3, 2026, while the latest company filings still frame the story through revenue, losses, and cash use.

VRCA stock for Verrica Pharmaceuticals (US92511P1021) closed at $1.41 in the latest quote snapshot, with a market capitalization of $43.64 million and 8,021 shares traded. The stock price sets the frame; the business figures set the tension.

Latest numbers still matter

In the most recent reported quarter, Verrica posted revenue of $1.0 million and a net loss of $18.5 million. That is a wide gap for a company of this size, and it keeps operating leverage in the spotlight.

Cash and equivalents stood at $24.8 million at June 30, 2026, while the quarter showed cash used in operating activities of $15.2 million. A burn rate of that scale matters because it shortens the runway between financing decisions.

What the market sees

The latest trading snapshot also showed the shares at a 52-week range between $0.95 and $2.34. At $1.41, the stock sits above the low and well below the high, which leaves room for sharp moves in either direction.

For investors, the comparison is simple: revenue of $1.0 million versus a net loss of $18.5 million in the latest quarter is still the key ratio to watch. Until that narrows, valuation will stay tied more to liquidity than to sales momentum.

Go deeper

Verrica Pharmaceuticals revenue and cash burn

The latest quarter shows how far revenue still has to scale before the loss profile changes.

Tapinarof stays central

Verrica's core commercial story remains tied to tapinarof, the company's topical treatment platform for dermatology. The product line is the practical test of whether revenue can move beyond a $1.0 million quarterly base.

Price and scale

As of September 3, 2026, the shares were priced at $1.41, with market value at $43.64 million. That combination of low absolute price and small equity value keeps the stock sensitive to every filing and sales update.

Verrica Pharmaceuticals at a glance

  • Company: Verrica Pharmaceuticals Inc.
  • ISIN: US92511P1021
  • Ticker: VRCA
  • Trading venue: NASDAQ
  • Price (as of September 3, 2026): $1.41 USD
  • Market capitalization: $43.64 million USD (as of September 3, 2026)
  • Sector / Industry: Health Care / Biotechnology
  • Index membership: None
Disclaimer...
en | US92511P1021 | VRCA | boerse | 70050641 |